Qiagen N.V. income statement QGEN

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Qiagen N.V. reported revenue of $2.1 billion, up 5.7% from the year before. Net income was $424.9 million, a profit margin of 20.3%. Operating income came to $465.9 million, an operating margin of 22.3%. Diluted earnings per share were $1.94. Across the 10 fiscal years shown, revenue grew from $1.3 billion in fiscal 2016 to $2.1 billion in fiscal 2025, about 5.1% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
FY 2018
Dec 31, 2018
FY 2017
Dec 31, 2017
FY 2016
Dec 31, 2016
Revenue
2,090
+5.7%
1,978
+0.7%
1,965
-8.2%
2,142
-4.9%
2,252
+20.4%
1,870
+22.5%
1,526
+1.6%
1,502
+5.9%
1,418
+5.9%
1,338
+4.5%
Cost of revenue
791
-21.8%
1,011
+38.2%
732
-3.3%
757
-5.5%
801
+25.6%
638
+22.3%
521
+4.0%
501
+1.2%
495
+0.3%
493
+8.6%
Gross profit
1,299
+34.3%
967
-21.6%
1,234
-10.9%
1,385
-4.6%
1,451
+17.7%
1,233
+22.6%
1,005
+0.4%
1,001
+8.5%
923
+9.2%
845
+2.2%
Selling, general and administrative
584
+3.4%
564
-2.6%
579
-4.1%
604
+3.3%
584
+11.3%
525
+4.2%
504
+28.5%
392
+4.5%
376
-0.2%
376
+4.7%
Operating income
466
+376.8%
98
-76.2%
410
-22.9%
531
-15.7%
630
+63.1%
386
+1578.5%
-26
-109.8%
267
+73.8%
153
+55.2%
99
-44.9%
Interest income
64
-5.4%
68
-13.9%
79
+141.1%
33
+242.8%
10
-4.8%
10
-54.6%
22
+6.1%
21
+95.9%
11
+57.1%
7
+42.6%
Interest expense
33
-24.1%
44
—
—
—
—
—
—
—
—
Gain (loss) on investments
-1
-127.2%
-0
—
—
—
—
—
—
—
—
Other non-operating income (expense)
-7
-799.9%
-1
+87.1%
-6
-184.7%
7
-83.4%
41
-64.4%
114
+26364.4%
0
-92.3%
6
+140050.0%
-0
+100.0%
-10
+8.3%
Pretax income
490
+304.7%
121
-71.8%
430
-16.2%
513
-18.1%
626
+42.4%
439
+665.0%
-78
-134.5%
226
+97.4%
114
+101.0%
57
-58.2%
Income tax
65
+74.1%
38
-57.6%
89
-1.0%
89
-21.1%
113
+41.0%
80
+321.0%
-36
-202.7%
35
-52.2%
74
+416.2%
-23
-465.5%
Net income
425
+408.3%
84
-75.5%
341
-19.4%
423
-17.4%
513
+42.7%
359
+966.5%
-41
-121.8%
190
+371.3%
40
-49.8%
80
-38.2%
Basic EPS
1.96
+415.8%
0.38
-74.7%
1.50
-19.4%
1.86
-17.3%
2.25
+43.3%
1.57
+972.2%
-0.18
-121.4%
0.84
+366.7%
0.18
-47.1%
0.34
-39.3%
Diluted EPS
1.94
+424.3%
0.37
-75.0%
1.48
-19.6%
1.84
-16.7%
2.21
+44.4%
1.53
+950.0%
-0.18
-122.0%
0.82
+382.4%
0.17
-50.0%
0.34
-38.2%
Weighted average shares, basic
217
-2.4%
223
-2.4%
228
+0.3%
228
-0.2%
228
-0.2%
228
+0.7%
227
+0.1%
227
-0.6%
228
-2.9%
235
+0.6%
Weighted average shares, diluted
219
-2.6%
225
-2.6%
231
+0.2%
230
-0.8%
232
-0.9%
234
+3.3%
227
-2.9%
233
+0.2%
233
-2.5%
239
+0.1%
Other measures
Depreciation and amortization
194
-4.7%
203
-1.0%
205
-1.5%
208
-3.0%
215
+4.8%
205
-11.4%
231
+12.1%
206
-4.6%
216
+1.6%
213
+11.3%
EBITDA
660
+119.2%
301
-51.1%
615
-16.8%
740
-12.4%
845
+42.9%
591
+188.1%
205
-56.6%
473
+27.9%
370
+18.6%
312
-15.9%
Interest coverage
14.01x
2.23x
—
—
—
—
—
—
—
—
Margins
Gross margin
62.18%
48.90%
62.77%
64.65%
64.43%
65.91%
65.86%
66.65%
65.08%
63.13%
Operating margin
22.29%
4.94%
20.86%
24.82%
27.98%
20.66%
-1.71%
17.75%
10.82%
7.39%
Pretax margin
23.46%
6.12%
21.87%
23.94%
27.79%
23.50%
-5.10%
15.03%
8.07%
4.25%
Profit margin
20.33%
4.23%
17.37%
19.76%
22.77%
19.20%
-2.72%
12.68%
2.85%
6.01%
EBITDA margin
31.56%
15.21%
31.31%
34.55%
37.53%
31.62%
13.45%
31.50%
26.09%
23.31%
Effective tax rate
13.34%
31.00%
20.59%
17.44%
18.09%
18.27%
—
15.66%
64.68%
-41.11%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
QGEN (NYSE)
Fiscal year ends
December 31
Incorporated in
Netherlands
Headquarters
Pl Venlo
SEC filer status
Large accelerated filer
SEC CIK
1015820
Former names
QIAGEN NV (until Feb 14, 2020)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.